Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007146106 - PROCUREMENT, ISOLATION AND CRYOPRESERVATION OF MATERNAL PLACENTAL CELLS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

WHAT IS CLAIMED IS:
1. A method for obtaining a population of cells comprising maternal placental stem cells, the method comprising:
(a) disaggregating placental tissue and separating the population of cells from disaggregated placental tissue;
(b) collecting and concentrating the population of cells; and
(c) cryopreserving the population of placental cells at or below about -135°.
2. The method of claim 1, wherein the maternal placental stem cells express the cell surface marker CDl 17 and at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD105, CD166, SSEA-3 and SSEA-4 and have low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45 and CDl 33 from placental tissue.
3. A process for obtaining a population of cells comprising maternal placental stem cells, the method comprising:
(a) procuring placental tissue from a whole placenta, the placental tissue comprising maternal tissue and fetal tissue;
(b) disaggregating the placental tissue;
(c) isolating the population of cells comprising maternal placental cells from disaggregated maternal tissue; and
(d) collecting the population of cells comprising maternal placental stem cells by concentrating the population of placental cells with at least one step of centrifugation.
4. The process of claim 3, wherein the maternal placental stem cells express the cell surface marker CDl 17 and at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD105, CD166, SSEA-3 and SSEA-4 and have low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45 and CDl 33 from placental tissue.
5. A process for collecting maternal placental stem cells expressing CDl 17 from placental tissue, the process comprising:
(a) isolating placental cells comprising the maternal placental stem cells from the placental tissue by disaggregating the placental tissue;
(b) collecting and concentrating the placental cells; and
(c) cryopreserving the placental cells.
6. The process of claim 5, wherein the maternal placental stem cells also express at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD105, CD166, SSEA-3 and SSEA-4 and have low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45 and CD 133 from placental tissue.
7. A system for collecting a population of cells comprising maternal placental stem cells, comprising:
(a) a placental cell isolater, wherein the placental cell isolator disaggregates placental tissue comprising maternal tissue and separates placental cells from the disaggregate placental tissue;
(b) a placental cell collector, wherein the placental cell collector collects the placental cells separated from the disaggregate placental tissue:
(c) a placental cell concentrator, wherein the placental cell concentrator concentrates placental cells present in a suspension; and (d) a placental cell cryopreserver, wherein the placental cell cryopreserver maintains the collected and concentrated placental cells at a temperature at or below about -1350C.
8. A process for isolating maternal placental stem cells expressing CDl 17 from a population of placental cells, the process comprising:
(a) culturing a population of placental cells comprising maternal placental stem cells;
(b) selecting placental cells expressing CDl 17 from a culture of the population of placental cells; and
(c) cryopreserving the maternal placental stem cells expressing CD 117.
9. The process of claim 8, wherein the maternal placental stem cells also express at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD 105, CD 166, SSEA-3 and SSEA-4 and have low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45 and CD133 from placental tissue.
10. A process for isolating a population of maternal placental stem cells from a population of placental cells, comprising, selecting maternal placental stem cells expressing CDl 17 from a culture of the population of placental cells.
11. A process for isolating a population of maternal placental stem cells expressing CDl 17 from a population of placental cells, the process comprising,
(a) selecting placental cells expressing CDl 17 from a population of placental cells comprising maternal placental stem cells;

(b) culturing the placental cells expressing CDl 17 selected from the population of placental cells comprising maternal placental stem cells; and
(c) selecting placental cells expressing CDl 17 from a culture of placental cells.
12. A population of cells enriched for maternal placental stem cells obtained from the process comprising:
(a) culturing a population of cells comprising maternal placental stem cells; and
(b) selecting cells expressing CD 117 from a culture of the population of cells.

13. A population of maternal placental stem cells obtained from the process comprising selecting placental cells expressing CDl 17 from a culture of a population of placental cells.
14. The population of maternal placental cells of claim 13, wherein the maternal placental stem cells express the cell surface marker CDl 17 and at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD 105, CD 166, SSEA-3 and SSEA-4 and have low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45 and CDl 33 from placental tissue.
15. Maternal placental stem cells obtained from the process comprising
(a) selecting placental cells expressing CDl 17 from a population of placental cells comprising maternal placental stem cells;
(b) culturing the placental cells expressing CDl 17 selected from the population of placental cells comprising maternal placental stem cells; and (c) selecting placental cells expressing CDl 17 from a culture of placental cells expressing CDl 17.
16. A population of cells enriched for maternal placental stem cells expressing CDl 17.
17. A population of cells enriched for maternal placental stem cells express the cell surface marker CDl 17 and at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD105, CD166, SSEA-3 and SSEA-4 and have low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45 and CD 133 from placental tissue.
18. A population of cells enriched for maternal placental stem cells expressing CD44 and CDl 17 and having low or no expression of CD45.
19. A composition comprising a population of cells enriched for maternal placental stem cells and a preservation agent.
20. A composition comprising at least one maternal placental stem cell and a preservation agent.
21. The composition of claim 20, wherein the at least one maternal placental stem cell expresses at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD105, CDl 17, CD166, SSEA-3 and SSEA-4 and has low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45 and CD 133 and a preservation agent.
22. At least one maternal placental stem cell obtained from the process comprising:
(a) procuring placental tissue comprising maternal tissue and fetal tissue from a whole placenta;

(b) disaggregating the placental tissue;
(c) isolating placental cells comprising maternal placental stem cells from disaggregated placental tissue;
(d) collecting and concentrating placental cells comprising maternal placental stem cell in a population of cells;
(e) culturing the population of placental cells comprising maternal placental stem cell; and
(f) selecting at least one maternal placental stem cell expressing CDl 17 from a culture of the population of placental cells.
23. The process of claim 22, wherein the process comprises the further steps of:
(a) culturing at least one maternal placental stem cell expressing CDl 17 selected from the population of placental ceils; and
(b) selecting at least one maternal placental stem cell expressing CDl 17 from a culture of placental cells expressing CDl 17 comprising a population of at least one maternal placental stem cell expressing CDl 17.